The board of directors at their meeting held this week, has approved his appointment as a chief financial officer of the company effective December 1, 2020.
In a career spanning over 33 years, Agarwal has held several leadership positions, contributing significantly to the financial performance of his organizations.
With over 10 years of working experience in several countries outside India, he brings global experience in leading business and financial strategy, transforming finance function, as well as in M and A-strategy and execution.
Agarwal has expertise in driving performance management of investments, financial result delivery and driving operating margin improvement through revenue and cost optimization across the value chain.
He joins Dr. Reddy's from Reckitt Benckiser plc, where he was CFO-Health, based in London.
Saumen Chakraborty, president and CFO, will retire effective December 1, 2020.
In his 19+ years career at Dr. Reddy's, Saumen has contributed significantly, leading functions such as HR, Global Generics Operations, Quality, Finance, Legal and Digital and Process Excellence. Saumen will continue to be associated with the company as an Advisor.
He will also help Agarwal to transition effectively.
Reddy's Laboratories is an integrated pharmaceutical company. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe.
The company's major markets include USA, India, Russia and CIS countries, and Europe.
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling